Medtronic acquires CathWorks

Medtronic has finalized its acquisition of CathWorks for $585 million, marking a strategic addition to its cardiovascular care portfolio. The completion of this transaction integrates CathWorks’ FFRangio system, an innovative AI-driven tool for angiography-derived physiologic assessment that eliminates the need for drugs and wire-based procedures. This deal is positioned to enhance Medtronic’s standing in the medical device sector, specifically in the management and treatment of coronary artery disease.

The acquisition, completed on April 20, 2026, could include additional undisclosed earn-outs. The FFRangio system from CathWorks is commercially available in key markets including the U.S., Europe, and Japan. This system has demonstrated non-inferiority to traditional wire-based fractional flow reserve assessments in the ALL-RISE trial, which involved over 1,900 patients. Medtronic has indicated that the transaction will be immaterial to its fiscal 2027 GAAP and adjusted EPS but is expected to have a neutral to accretive impact in subsequent periods.

Medtronic’s acquisition of CathWorks aims to transform patient care in the cardiovascular space. The FFRangio system offers a streamlined assessment method, potentially improving physician efficiency and patient outcomes. Ramin Mousavi, CEO of CathWorks, highlighted the shared commitment of both companies to revolutionize cardiac care. This build-on to their previous 2022 strategic partnership underlines Medtronic’s intent to expand its offerings in interventional cardiology.

The deal takes place against a backdrop of ongoing consolidation in the medical device industry, where companies seek to bolster portfolios with innovative technologies amid competitive pressures. Medtronic’s acquisition aligns with broader trends of integrating AI and digital health technologies. While some market skepticism was evident with a mild stock decline on the deal's announcement, the integration of CathWorks' technology is anticipated to drive long-term growth in the cardiovascular segment.

Looking ahead, Medtronic will focus on the successful integration of CathWorks’ technology. The impact on clinical practice and the potential for broader adoption of AI-based assessments will be key evaluation points. Any additional potential earn-outs and regulatory transitions will be monitored closely as Medtronic leverages the FFRangio system to enhance its market share and clinical capabilities in the cardiovascular domain.